ICH Consults On Standardizing Benefit-Risk Information In CTD Drug Submissions
This article was originally published in SRA
Executive Summary
The International Conference on Harmonisation is inviting feedback on proposed changes to how drug companies should present the benefits and risks of their drug in Module 2 of the common technical document (CTD)1,2. The proposed changes aim to standardize the presentation of benefit-risk information in regulatory submissions using the CTD format.
You may also be interested in...
ICH Takes Flexible Approach On Presenting Benefit-Risk Assessment In Drug Submissions
The International Council for Harmonisation's final guidance on standardizing benefit-risk information in drug submissions is expected to support regulatory decision-making through a more consistent description of information.
Pakistan Explains Updated Risk-Based Criteria For GCP Inspections
Pakistan’s drug regulator is hoping that improved transparency on its inspection protocols will help research entities better prepare for good clinical practice inspections.
UK MHRA Inspector Highlights Mistakes Made In Decentralized Clinical Trials
Inadequate risk assessments, participant confidentiality breaches and issues with documenting and verifying clinical trial activities have emerged as recurring themes in inspections of decentralized clinical trials by the UK medicines regulator.